

APOA1 Human

Apolipoprotein A-I Human Recombinant

CYK0043

Product Overview

Name	APOA1 Human
Accession(Primary)	P02647
Description	Apolipoprotein A-I Human Recombinant

Target information (P02647)

Gene Name

About Gene Symbol

Background

Apolipoprotein A-I Human Recombinant: A Promising Therapeutic Agent for Cardiovascular Diseases

Abstract: Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide. Dyslipidemia, characterized by abnormal lipid profiles, is a significant risk factor for the development of CVDs. Apolipoprotein A-I (ApoA-I) is the primary protein component of high-density lipoprotein (HDL), known as the "good cholesterol." ApoA-I plays a crucial role in reverse cholesterol transport, promoting the efflux of cholesterol from peripheral tissues to the liver for elimination. Recombinant ApoA-I offers a potential therapeutic strategy for enhancing HDL functionality and reducing CVD risk. This research paper aims to provide an overview of ApoA-I human recombinant, its production methods, and its therapeutic applications in cardiovascular medicine.

Introduction Cardiovascular diseases and dyslipidemia Role of apolipoprotein A-I in reverse cholesterol transport Potential of ApoA-I human recombinant as a therapeutic agent Structure and Function of Apolipoprotein A-I Primary structure and domains of ApoA-I Functional properties of ApoA-I in reverse cholesterol transport Interaction with other lipoproteins and cellular receptors Production of Apolipoprotein A-I Human Recombinant Expression systems for recombinant ApoA-I Biotechnological methods for large-scale production Purification and

characterization of recombinant ApoA-I Therapeutic Applications of Apolipoprotein A-I Human
Recombinant Promotion of reverse cholesterol transport Anti-inflammatory and antioxidant effects
Enhancement of endothelial function Cardioprotective effects in animal models Clinical Trials and Future
Perspectives Phase I and II clinical trials Challenges and limitations Future directions and potential
therapeutic combinations Conclusion Summary of the potential of ApoA-I human recombinant as a
therapeutic agent for CVDs Importance of ongoing research and clinical trials